Frederic D. Bushman

University of Pennsylvania — United States

Immunology and Microbiology · Life Sciences

138h-index122.8kcitations766works3.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV Research and Treatment(171), CAR-T cell therapy research(152), HIV/AIDS drug development and treatment(120), CRISPR and Genetic Engineering(113), Virus-based gene therapy research(109)

Publications765 total

Hematopoietic Stem-Cell Gene Therapy for Cystinosis
New England Journal of Medicine·2026· 1 citedOpen Access
Figure S11 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S6 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S4 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S8 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S9 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Table S2 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S2 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S3 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Table S1 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S7 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S5 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S10 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S1 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Human gut prophage landscape identifies a prophage-mediated fucosylation mechanism alleviating colitis
Nature Communications·2025Open Access
Baseline intestinal microbiota composition influences response to a real-world dietary fiber intervention
npj Biofilms and Microbiomes·2025· 2 citedOpen Access
Patient-informed CRISPR screening reveals gene targets to improve CAR T-cell efficacy
Blood·2025Open Access
CCR5 blockade: A therapeutic approach to uncouple CART-BCMA expansion from CART-mediated immune toxicities.
Blood·2025Open Access
Toward ‘n of one’ gene therapies: Scalable ex vivo adenine base editing via lipid nanoparticles in a sickle cell disease model
Blood·2025Open Access
Long-term follow-up of the first in human post-transcriptional genetic silencing of BCL11A in sickle cell disease in a phase 1 pilot and feasibility trial
Blood·2025
page 1 of 39Next →

Frequent Co-authors

Kyle Bittinger(12), Gary D. Wu(12), James D. Lewis(11), Rob Knight(10), Hongzhe Li(9), Christian Hoffmann(7), Rohini Sinha(7), Carl H. June(7), Dan Knights(6), Ronald G. Collman(6), Bruce L. Levine(6), Christopher L. Nobles(6), Catherine Lozupone(5), Emily S. Charlson(5), Joseph A. Fraietta(5), Irina Kulikovskaya(5), Simon F. Lacey(5), Scott T. Kelley(4), Robert N. Baldassano(4), Charles C. Berry(4)